Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HLN
stocks logo

HLN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
2.81B
+1.7%
0.000
-100%
Estimates Revision
The market is revising Upward the revenue expectations for Haleon plc (HLN) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by -3.15%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.47%
In Past 3 Month
Stock Price
Go Down
down Image
-3.15%
In Past 3 Month
Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.530
sliders
Low
13.44
Averages
13.44
High
13.44
Current: 9.530
sliders
Low
13.44
Averages
13.44
High
13.44
Berenberg
Bethan Davies
Buy
maintain
2025-11-07
Reason
Berenberg
Bethan Davies
Price Target
2025-11-07
maintain
Buy
Reason
Berenberg analyst Bethan Davies raised the firm's price target on Haleon to 517 GBp from 507 GBp and keeps a Buy rating on the shares.
Barclays
Overweight -> Equal Weight
downgrade
2025-09-16
Reason
Barclays
Price Target
2025-09-16
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Haleon to Equal Weight from Overweight with a price target of 380 GBp, down from 430 GBp. The U.S. represents 34% of the company's sales and is seeing slower category growth and destocking, the analyst tells investors in a research note. The firm says Haleon has overweight exposure to declining U.S. drug stores. The company cut its 2025 outlook but there remains short-term risks, contends Barclays. It moves to the sidelines pending a plan from Haleon's new U.S. head.
Goldman Sachs
Olivier Nicolai
Neutral -> Buy
upgrade
£440
2025-09-10
Reason
Goldman Sachs
Olivier Nicolai
Price Target
£440
2025-09-10
upgrade
Neutral -> Buy
Reason
Goldman Sachs analyst Olivier Nicolai upgraded Haleon to Buy from Neutral with a 440 GBp price target. The firm sees the company's fundamentals inflecting in fiscal 2026 due to stronger volume, a U.S. recovery and ongoing high-single-digit Oral Health growth. With Haleon's organic sales growth positioned to accelerate into 2026, the shares are trading at an attractive entry point, the analyst tells investors in a research note.
Berenberg
Bethan Davies
Buy
downgrade
2025-08-12
Reason
Berenberg
Bethan Davies
Price Target
2025-08-12
downgrade
Buy
Reason
Berenberg analyst Bethan Davies lowered the firm's price target on Haleon to 500 GBp from 503 GBp and keeps a Buy rating on the shares.
Barclays
Overweight
to
NULL
downgrade
$475 -> $450
2025-07-08
Reason
Barclays
Price Target
$475 -> $450
2025-07-08
downgrade
Overweight
to
NULL
Reason
Barclays lowered the firm's price target on Haleon to 450 GBp from 475 GBp and keeps an Overweight rating on the shares.
Morgan Stanley
Overweight
to
Overweight
downgrade
2025-07-08
Reason
Morgan Stanley
Price Target
2025-07-08
downgrade
Overweight
to
Overweight
Reason
Morgan Stanley lowered the firm's price target on Haleon to 410 GBp from 425 GBp and keeps an Overweight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Haleon PLC (HLN.N) is 18.61, compared to its 5-year average forward P/E of 15.96. For a more detailed relative valuation and DCF analysis to assess Haleon PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
15.96
Current PE
18.61
Overvalued PE
22.47
Undervalued PE
9.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
13.98
Current EV/EBITDA
13.94
Overvalued EV/EBITDA
14.87
Undervalued EV/EBITDA
13.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.73
Current PS
2.83
Overvalued PS
2.98
Undervalued PS
2.48
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 142.48% over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HLN News & Events

Events Timeline

(ET)
2025-10-08
09:24:14
Haleon Chooses Salesforce to Enhance Healthcare Professional Engagement Using AI
select
2025-07-06 (ET)
2025-07-06
20:12:33
Haleon breaks ground on new GBP 130M global oral health center
select
2025-06-24 (ET)
2025-06-24
08:08:06
Haleon names Carl Haney as Chief Research & Development Officer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-24Newsfilter
Altibbi Partners with Haleon to Promote Oral Health in Saudi Arabia
  • Partnership Formation: Altibbi, the leading digital health platform in the Arab world, partnered with Haleon to enhance oral health awareness through the Healthy Saudi Smile campaign in Saudi Arabia.
  • Educational Initiative: The campaign focuses on preventive care and oral health education, connecting users with certified doctors for instant consultations.
  • Digital Access: Altibbi enabled Haleon to provide reliable Arabic-language oral health advice, significantly increasing user engagement and facilitating health actions.
  • Future Expansion: Altibbi plans to expand similar collaborations with health brands, offering integrated solutions that connect education, access, and action to improve everyday health outcomes.
[object Object]
Preview
2.0
11-14NASDAQ.COM
Positive Cross of the Two Hundred Day Moving Average - HLN
  • 52 Week Range: HLN's stock has a 52-week low of $8.71 and a high of $11.42, with the last trade recorded at $9.90.
  • Market Analysis: The article mentions other stocks that have recently crossed above their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information provides insight into HLN's stock performance within the context of its recent trading activity.
[object Object]
Preview
4.5
11-10NASDAQ.COM
Most Active Stocks in Pre-Market Trading on November 10, 2025: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS

  • NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 380.3 points to 25,440.11, with a total pre-market volume of 219,886,694 shares traded.

  • Active Stocks Overview: InflaRx N.V. (IFRX) and Greenidge Generation Holdings Inc. (GREE) are among the most active stocks, with IFRX trading at $2.01 and GREE at $2.02, both showing positive movements.

  • Earnings Reports and Forecasts: IFRX and Innate Pharma S.A. (IPHA) are scheduled to release earnings reports soon, with IPHA showing a significant forecasted increase in earnings per share compared to last year.

  • Stock Recommendations: Several stocks, including NVIDIA Corporation (NVDA) and IonQ, Inc. (IONQ), are currently in the "buy range" according to Zacks, indicating positive market sentiment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Haleon PLC (HLN) stock price today?

The current price of HLN is 9.53 USD — it has increased 0.21 % in the last trading day.

arrow icon

What is Haleon PLC (HLN)'s business?

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

arrow icon

What is the price predicton of HLN Stock?

Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Haleon PLC (HLN)'s revenue for the last quarter?

Haleon PLC revenue for the last quarter amounts to 2.63B USD, decreased -5.33 % YoY.

arrow icon

What is Haleon PLC (HLN)'s earnings per share (EPS) for the last quarter?

Haleon PLC. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Haleon PLC (HLN)'s fundamentals?

The market is revising Upward the revenue expectations for Haleon plc (HLN) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by -3.15%.
arrow icon

How many employees does Haleon PLC (HLN). have?

Haleon PLC (HLN) has 24622 emplpoyees as of December 05 2025.

arrow icon

What is Haleon PLC (HLN) market cap?

Today HLN has the market capitalization of 42.44B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free